What is WINSTROL
WINSTROL (anabolic steroids) , brand of stanozolol tablets, is an anabolic steroid, a synthetic derivative of testosterone. Each tablet for oral administration contains 2 mg of stanozolol. It is designated chemically as 17-methyl-2′ H -5(alpha)-androst-2-eno[3,2- c ]pyrazol-17(beta)-ol.
Inactive Ingredients: Dibasic Calcium Phosphate, D&C Red #28, FD&C Red #40, Lactose, Magnesium Stearate, Starch
DOSAGE AND ADMINISTRATION
Winstrol. Winstrol (anabolic steroids) is a synthetic steroid, similar to testosterone, used in the treatment of hereditary angioedema, which causes episodes of swelling of the face, extremities, genitals, bowel wall, and throat. Winstrol may decrease the frequency and severity of these attacks.Generic Name: anabolic steroids
In adolescent and adult males, side effects of Winstrol may include frequent or persistent erections of the penis, and the appearance or aggravation of acne. In women, side effects of Winstrol may include hoarseness, acne, changes in menstrual periods, or more facial hair.
The use of anabolic steroids such as Winstrol may be associated with serious adverse reactions, many of which are dose related. Patients should be placed on the lowest possible effective dose. Medications that may interact with Winstrol include anticoagulants (blood thinners), insulin, or an oral diabetes medicine. Tell your doctor all medications you are taking. Winstrol is known to cause birth defects in a fetus. Do not take this medication if you are pregnant or could become pregnant during treatment. It is not known whether Winstrol is excreted in human milk. Many drugs are excreted in human milk and there is the potential for adverse reactions in nursing infants from anabolic steroids. Consult your doctor before breastfeeding.
Our Winstrol (anabolic steroids) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
DOSAGE AND ADMINISTRATION
The use of anabolic steroids may be associated with serious adverse reactions, many of which are dose related; therefore, patients should be placed on the lowest possible effective dose.
Hereditary Angioedema. The dosage requirements for continuous treatment of hereditary angioedema with WINSTROL (anabolic steroids) should be individualized on the basis of the clinical response of the patient. It is recommended that the patient be started on 2 mg, three times a day. After a favorable initial response is obtained in terms of prevention of episodes of edematous attacks, the proper continuing dosage should be determined by decreasing the dosage at intervals of one to three months to a maintenance dosage of 2 mg a day. Some patients may be successfully managed on a 2 mg alternate day schedule. During the dose adjusting phase, close monitoring of the patient’s response is indicated, particularly if the patient has a history of airway involvement.
The prophylactic dose of WINSTROL (anabolic steroids) , to be used prior to dental extraction, or other traumatic or stressful situations has not been established and may be substantially larger.
Attacks of hereditary angioedema are generally infrequent in childhood and the risks from stanozolol administration are substantially increased. Therefore, long-term prophylactic therapy with this drug is generally not recommended in children, and should only be undertaken with due consideration of the benefits and risks involved (see PRECAUTIONS, Pediatric Use ).
Anabolic steroids may cause suppression of clotting factors II, V, VII, and X, and an increase in prothrombin time.
Women should be observed for signs of virilization (deepening of the voice, hirsutism, acne, and clitoromegaly). To prevent irreversible change, drug therapy must be discontinued, or the dosage significantly reduced when mild virilism is first detected. Such virilization is usual following androgenic anabolic steroid use at high doses. Some virilizing changes in women are irreversible even after prompt discontinuance of therapy and are not prevented by concomitant use of estrogens. Menstrual irregularities may also occur.
PELIOSIS HEPATIS, A CONDITION IN WHICH LIVER AND SOMETIMES SPLENIC TISSUE IS REPLACED WITH BLOOD-FILLED CYSTS, HAS BEEN REPORTED IN PATIENTS RECEIVING ANDROGENIC ANABOLIC STEROID THERAPY. THESE CYSTS ARE SOMETIMES PRESENT WITH MINIMAL HEPATIC DYSFUNCTION, BUT AT OTHER TIMES THEY HAVE BEEN ASSOCIATED WITH LIVER FAILURE. THEY ARE OFTEN NOT RECOGNIZED UNTIL LIFE-THREATENING LIVER FAILURE OR INTRA-ABDOMINAL HEMORRHAGE DEVELOPS. WITHDRAWAL OF DRUG USUALLY RESULTS IN COMPLETE DISAPPEARANCE OF LESIONS.
LIVER CELL TUMORS ARE ALSO REPORTED. MOST OFTEN THESE TUMORS ARE BENIGN AND ANDROGEN-DEPENDENT, BUT FATAL MALIGNANT TUMORS HAVE BEEN REPORTED. WITHDRAWAL OF DRUG OFTEN RESULTS IN REGRESSION OR CESSATION OF PROGRESSION OF THE TUMOR. HOWEVER, HEPATIC TUMORS ASSOCIATED WITH ANDROGENS OR ANABOLIC STEROIDS ARE MUCH MORE VASCULAR THAN OTHER HEPATIC TUMORS AND MAY BE SILENT UNTIL LIFE-THREATENING INTRA-ABDOMINAL HEMORRHAGE DEVELOPS.
BLOOD LIPID CHANGES THAT ARE KNOWN TO BE ASSOCIATED WITH INCREASED RISK OF ATHEROSCLEROSIS ARE SEEN IN PATIENTS TREATED WITH ANDROGENS AND ANABOLIC STEROIDS. THESE CHANGES INCLUDE DECREASED HIGH-DENSITY LIPOPROTEIN AND SOMETIMES INCREASED LOW-DENSITY LIPOPROTEIN. THE CHANGES MAY BE VERY MARKED AND COULD HAVE A SERIOUS IMPACT ON THE RISK OF ATHEROSCLEROSIS AND CORONARY ARTERY DISEASE.
Cholestatic hepatitis and jaundice occur with 17-alpha-alkylated androgens at relatively low doses. If cholestatic hepatitis with jaundice appears, the anabolic steroid should be discontinued. If liver function tests become abnormal, the patient should be monitored closely and the etiology determined. Generally, the anabolic steroid should be discontinued although in cases of mild abnormalities, the physician may elect to follow the patient carefully at a reduced drug dosage.